Comparative Pharmacology
Head-to-head clinical analysis: CORMAX versus DERMACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORMAX versus DERMACORT.
CORMAX vs DERMACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response.
2.5 mg orally twice daily; maximum 10 mg/day.
Apply a thin film to affected area twice daily (every 12 hours) for up to 2 weeks.
None Documented
None Documented
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h); clinical context: dosing every 4-6 hours to maintain therapeutic levels
Terminal elimination half-life is approximately 2-3 hours for hydrocortisone, the active component. Due to its short half-life, it requires multiple daily doses for sustained effect.
Renal: 90% unchanged; minor biliary/fecal: <5%
Primarily hepatic metabolism; metabolites are excreted renally (~75% as glucuronide and sulfate conjugates) and fecally (~25%). Less than 5% of the dose is excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid